Andrew
Toy

Andrew Toy runs a Medicare Advantage insurer with the instincts of a systems architect. His company, Clover Health, is not competing on call center staffing or broker relationships. It is competing on a proprietary AI platform called Clover Assistant that sits inside physician exam rooms and surfaces data doctors would otherwise miss. When the assistant flags that a patient is on a trajectory toward diabetic crisis - three years before standard diagnostic criteria would catch it - that is not a marketing claim. It is a clinical outcome, measured and reported, now on record before Congress.

In September 2025, Toy testified before the U.S. House Committee on Energy and Commerce. He did not show up with talking points about potential. He brought outcomes. Clover's members with congestive heart failure: 18% fewer hospitalizations. With COPD: 15% fewer hospitalizations. These are the numbers that change how investors, doctors, and policymakers think about what a Medicare plan can actually be.

Q1 2026 delivered something Toy's predecessors never managed: a GAAP Net Income of $27 million. That is not a one-quarter accounting trick - it is the first profitable quarter in Clover's history, arrived at while the company simultaneously posted 51% year-over-year membership growth and $749 million in revenue (up 62% year-over-year). His full-year 2026 guidance calls for $2.81-2.92 billion in revenue. For context, Clover's annual revenue in 2022 was under $800 million.

Toy moved from Hong Kong to the United States at 16 to study computer science at Stanford. He was not following a playbook - this was 1996, when the dotcom boom was just warming up and "software eating the world" was still a decade away from becoming a cliche. He earned both his BS and MS in computer science there, and then turned around and taught the introductory course, CS106A/X, one of the most enrolled classes on campus. If you know Stanford's CS program, you know that CS106A is where future engineers learn to think. Toy was the one writing the assignments and running the teaching team.

From academia he moved to Morgan Stanley as Vice President of Mobile Applications, leading wireless and mobility technologies and becoming the central owner of mobile security for the firm. Then to MTV Networks as Head of Mobile and Syndication Businesses Technical Direction, where he built the content delivery infrastructure that carried MTV's video to Verizon, AT&T, Xbox, and Netflix. Finance to media. Two very different industries, same underlying skill: making complex technical platforms actually work at scale.

At Google, Toy became Director of the Android Enterprise Group, leading Android for Work - the platform that made Android viable for corporate IT deployment. He then moved to Google Cloud, running Machine Learning, Enterprise Search, and Analytics for what would become G-Suite. By the time he left for Clover Health in 2018, he had spent four years at the center of how Google thinks about enterprise software.

The easy answer is that Toy saw a market opportunity at the intersection of machine learning and insurance data. The true answer is more personal. His father died from an aortic dissection - a consequence of uncoordinated care. Toy himself was diagnosed with Marfan syndrome at 17, and has managed the condition with regular physician visits for over 25 years. He is not an outsider opining on healthcare. He has been a patient navigating the same fragmented system he is now trying to fix.

He joined Clover Health in February 2018 as CTO. The company was already unusual: a Medicare Advantage plan that had built its own data infrastructure rather than outsourcing it. Toy added the President title in March 2019 and joined the board. When the CEO role opened at the start of 2023, he stepped into it. The transition was not ceremonial - Toy had been the technical architect behind Clover Assistant, the platform that differentiates the company from every other Medicare Advantage plan in the country.

In 2021, the Marfan Foundation named Toy an advisor to its board of directors - a signal of how seriously the healthcare community takes both his personal advocacy and his technical credentials. In 2025, he volunteered in creating the Marfan Foundation AI Community Companion, an AI tool for people living with Marfan syndrome. The distinction between his professional work at Clover and his advocacy work at the Marfan Foundation is thinner than it looks: both are about using data to help people with chronic conditions get care before crisis arrives.

Toy's approach to physician relationships is deliberately different from how most managed care companies operate. Traditional Medicare Advantage plans monitor physicians for cost and compliance. Clover's model is closer to providing physicians with a research assistant who has already read everything about this specific patient - their claims history, their lab trends, their medication adherence patterns - and surfaced what matters before the patient walks in the room.

The Reverse Mullet Healthcare Podcast episode featuring Toy - titled "Educating and Empowering Instead of Enforcing" - captured his philosophy in a phrase. He is not building a system that tells physicians what to do. He is building one that shows them what they might otherwise miss. The distinction matters enormously for physician adoption. Doctors who feel surveilled leave the network. Doctors who feel supported stay and engage more deeply.

This philosophy has coincided with significant membership growth. Clover reported 53% year-over-year growth during the 2025 Annual Enrollment Period, reaching 153,000 members as of January 1, 2026. By Q1 2026, membership was at 155,773. The company's 2026 full-year guidance projects 154,000-158,000 average members - a number that would have seemed implausible three years ago.

Toy is also explicit about where the opportunity comes from. Larger Medicare Advantage players - UnitedHealth, Humana, CVS/Aetna - are grappling with cost pressures, flat 2027 payment rates, and strategic retreats from certain markets. When big incumbents exit markets or cut benefits, that creates space for a differentiated, technology-native insurer to step in. Clover is positioned to absorb that displacement. Health equity - serving underserved populations, rural seniors, communities with historically poor access - is not just a mission statement for Toy. It is the growth thesis.

On September 3, 2025, Andrew Toy sat before the U.S. House Committee on Energy and Commerce Subcommittee on Health and made the case for responsible AI adoption in healthcare. He was not testifying as a lobbyist or a policy advocate. He was presenting clinical data from a system that is already running. Clover's AI had, at that point, processed years of physician interactions, flagged early disease markers, and produced measurable improvements in hospitalizations and readmissions for some of the highest-risk Medicare beneficiaries in the country.

His ask of Congress was specific: standardize data interoperability and promote policies that empower rather than replace healthcare providers. Not a request for special treatment. A request for the infrastructure that would let what Clover is doing be replicated more broadly. Gold House, the platform celebrating Asian American business leaders, recognized Toy for exactly this kind of impact - operating at the intersection of technical credibility and genuine public interest.

He is also, somewhat unusually for a CEO in this position, still a builder. Toy writes code. He was writing code as a child in Hong Kong, and the instinct - to understand systems by building them - runs through every role he has held. At Clover, that translates into a CEO who can have a substantive conversation with the engineering team about model architecture, not just quarterly KPIs. The result is an organization that moves faster on the product side than its insurance-industry peers would expect.